Get the Stockscreener App
4.27
0.47%
0.02
Exicure Inc stock is traded at $4.27, with a volume of 13,864.
It is up +0.47% in the last 24 hours and down -26.88% over the past month.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
See More
Previous Close:
$4.25
Open:
$4.37
24h Volume:
13,864
Relative Volume:
0.02
Market Cap:
$27.22M
Revenue:
$500.00K
Net Income/Loss:
$-7.88M
P/E Ratio:
-2.5207
EPS:
-1.694
Net Cash Flow:
$-5.49M
1W Performance:
+0.23%
1M Performance:
-26.88%
6M Performance:
-41.51%
1Y Performance:
-57.34%
1-Day Range:
$4.18
$4.40
1-Week Range:
$3.82
$4.56
52-Week Range:
$3.1006
$15.91
Exicure Inc Stock (XCUR) Company Profile
Name
Exicure Inc
Sector
Industry
Phone
847-673-1707
Address
2430 N. HALSTED ST., CHICAGO, IL
Compare XCUR vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.22 | 3.25B | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
8.69 | 536.01M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.32 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
2.8999 | 277.51M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DWLD
Davis Select Worldwide ETF
|
46.01 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-18-20 | Initiated | BMO Capital Markets | Outperform |
| Nov-20-19 | Initiated | Guggenheim | Buy |
Exicure Inc Stock (XCUR) Latest News
Exicure announces board and executive changes, CEO and CFO resignations By Investing.com - Investing.com India
Exicure announces board and executive changes, CEO and CFO resignations - Investing.com
Exicure Announces Major Leadership and Board Restructuring - TipRanks
Leadership shake-up at Exicure (NASDAQ: XCUR) as CEO, CFO and directors exit - Stock Titan
Why Exicure Inc. stock remains on watchlistsJuly 2025 Trends & Technical Pattern Recognition Alerts - mfd.ru
Aug Intraday: What is the Moat Score of Exicure IncTrade Risk Summary & Capital Protection Trading Alerts - baoquankhu1.vn
Exicure announces publication of results from Phase 2 study of burixafor - TipRanks
Exicure (XCUR) Publishes Promising Phase 2 Study Results for Bur - GuruFocus
Exicure (XCUR) Publishes Promising Phase 2 Study Results for Burixafor - GuruFocus
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - The Manila Times
Exicure, Inc. Publishes Phase 2 Study Results for Burixafor, a Novel CXCR4 Inhibitor in Hematologic Disease Treatment - Quiver Quantitative
Same-day stem cell collection seen in Exicure Phase 2 cancer trial - Stock Titan
Market Catalysts: Can Exicure Inc expand into new marketsJuly 2025 Chart Watch & High Conviction Buy Zone Picks - baoquankhu1.vn
Quarterly Earnings: Should I invest in NEPH before earningsWeekly Market Outlook & Daily Profit Maximizing Tips - baoquankhu1.vn
Jobs Data: Does Exicure Inc offer margin of safetyGap Up & Verified Entry Point Detection - baoquankhu1.vn
Trade Report: What is the Moat Score of Exicure Inc2025 Sector Review & Trade Opportunity Analysis - baoquankhu1.vn
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up - TipRanks
Market Trends: What is the Moat Score of Exicure IncJuly 2025 Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Exicure completes Phase 2 trial milestone and plans $1 million payment to GPCR Therapeutics - Investing.com UK
Exicure to Pay GPCR Therapeutics $1 Million for First Milestone Completion - 아시아경제
Exicure Achieves Milestone in Burixafor Phase 2 Program - TipRanks
Exicure Achieves First Milestone in Collaboration with GPCR Therapeutics - TradingView
Exicure to present phase 2 burixafor data at 2026 transplantation meeting - Investing.com Nigeria
Major Exicure Stakeholder Makes Bold Move With Large Share Sale - TipRanks
Insider Sell: Hitron Exicure Sells 258,367 Shares of Exicure Inc (XCUR) - GuruFocus
Exicure HiTron sells shares worth $1.16 million By Investing.com - Investing.com Nigeria
Exicure HiTron sells shares worth $1.16 million - Investing.com
Exicure to present data from burixafor Phase 2 trial at 2026 Tandem Meetings - TipRanks
Exicure (XCUR) to Showcase Phase 2 Trial Data on Burixafor at 20 - GuruFocus
Exicure, Inc. to Present Phase 2 Trial Results for Burixafor at 2026 ASTCT and CIBMTR Tandem Meetings - Quiver Quantitative
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings - The Manila Times
Exicure to Present Data From Burixafor Phase 2 Trial at the 2026 Tandem Meetings - 富途牛牛
Major Exicure Stakeholder Makes a Big Move With a Multi-Million Dollar Stock Sale - TipRanks
Exicure HiTron Inc sells $3.3m in Exicure (XCUR) stock By Investing.com - Investing.com Nigeria
Signal Recap: Whats the outlook for Exicure Incs sectorWeekly Trade Report & AI Based Buy and Sell Signals - baoquankhu1.vn
Insider Sell Alert: Hitron Exicure Sells 734,747 Shares of Exicu - GuruFocus
Exicure HiTron Inc sells $3.3m in Exicure (XCUR) stock - Investing.com
Understanding Momentum Shifts in (XCUR) - Stock Traders Daily
Exicure (NASDAQ:XCUR) Stock Rating Upgraded by Wall Street Zen - Defense World
Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 42.7% in December - Defense World
Exicure (NASDAQ:XCUR) Shares Up 1.2% – Time to Buy? - Defense World
Insider Sale: 10% owner at $XCUR Sells 741,272 Shares | XCUR Stock News - Quiver Quantitative
Why Exicure Inc. (2H0) stock attracts HNW investorsJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - Улправда
Exicure presents topline data from burixafor combination trial - MSN
Exicure HiTron sells $3.3m in Exicure shares By Investing.com - Investing.com South Africa
Exicure Hitron Sells Over 740K Shares - TradingView — Track All Markets
Exicure HiTron sells $3.3m in Exicure shares - Investing.com
Why Exicure Inc. stock is rated strong buyMarket Growth Review & Daily Stock Trend Watchlist - ulpravda.ru
Exicure Inc Stock (XCUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):